Research

  • Access to all necessary nuclear and GMP facilities
  • Nuclear R&D and operational expertise
  • Partnership representing the full expertise and capabilities
Our research focuses on the development of new radiopharmaceutical products, based on the availability of both high potential medical isotopes and dedicated nuclear infrastructure. We aim for products with a high possibility of adding value to nuclear medicine, more specifically for cancer treatment.

Straight to

  • Medical isotope in high demand
  • Beta-emitter
  • Independent supply from in-house FIELD-LAB process
More Information
  • High quality
  • Chemotherapeutic compound (cisplatin) with Pt-195m integrated by synthesis
  • For in-human use
  • Chemotherapeutic function unaltered
More Information
  • Beta-emitter with limited recoil, and a single alpha emission in the decay chain
  • Ideal half-life (~10 hrs.)
  • Reliable supply
More Information

Lead 212

Pb-212 is a medical isotope with great perspective for cancer therapy; the isotope offers maximal efficiency and minimal side effects.

Pb-212 has a half-life of 11 hours: long enough for targeting purposes, short enough and with a single alpha-emission to avoid long term, off-target damage.

Pb-212 production is complex and is difficult to get access to. FIELD-LAB has managed to achieve unlimited availability by developing its own, in-house production process. In addition, FIELD-LAB operates the facilities autonomously making it flexible in assigning resources and using this high potential isotope for R&D purposes.

Read more

SMALL JK NRG Petten Arnhem 3236
CISSPECT PT 195M

Pt-195m CISSPECT

Pt-195m CISSPECT is a promising imaging agent to measure the distribution of cisplatin chemotherapy in the patient. It can possibly be used to predict the effectivity of cisplatin treatment and/or to determine potential toxicity.

The prediction outcome can then serve as input to optimise the individual patient treatment and to determine whether cisplatin treatment is useful. Or if alternatives should be considered, due to expected severe side effects such as kidney failure, loss of hearing, nausea and tiredness.

Lu-177 chloride n.c.a.

Currently, Lu-177 is dominating the clinical pipeline regarding the innovation of radiopharmaceuticals. Researchers have found numerous possible applications for this radio isotope.

We are looking to provide bio pharma and scientific partners with Lu-177 chloride (n.c.a.) and support their pre-clinical and clinical studies in the development of Lu-177 radiopharmaceuticals. These partners can range from (academic) hospitals to commercial start-ups.

Field LAB Lutetium 177

We add value to …

The development of new nuclear medicine.

Knowledge transfer, from science to industry.

Upscaling opportunities.

Publications

24 March 2020

Thanks to intensive collaboration between Curium and NRG, a complex project has been brought to a successful conclusion: the development and installation of a production process for the medical isotope Xenon-133.

13 October 2019

jodium-125

Two world leading research reactors join forces to create dual supply of medical isotope iodine-125

Publications